A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

SillaJen, Inc.18 sites in 3 countries89 target enrollmentJune 7, 2018

ConditionsRenal Cell Carcinoma

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Renal Cell Carcinoma
Sponsor: SillaJen, Inc.
Enrollment: 89
Locations: 18
Primary Endpoint: Maximum tolerated dose(MTD) / Maximum feasible dose (MFD)
Status: Active, not recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a Phase 1b/2a, open-label, multi-center, dose-escalation and safety/efficacy evaluation trial of Pexa-Vec plus Cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with Cemiplimab will be determined, followed by an expansion stage. During the expansion patients will receive Cemiplimab alone or in combination with Pexa-Vec, which will be administered either through intravenous (IV) or intratumoral (IT) injection.

Registry

clinicaltrials.gov

Start Date

June 7, 2018

End Date

November 2023

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

SillaJen, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Histologically or cytologically confirmed metastatic or unresectable clear cell renal cell carcinoma (ccRCC)
•Part 2 Arm D ONLY: Patients must be refractory to anti PD-1 or anti-PD-L1 (either as monotherapy or in-combination with other approved checkpoint inhibitors or targeted therapies according to their approved label) and patients must meet all of the following criteria:
•Received treatment of approved anti PD-1 or anti-PD-L1 (dosed per label of the country providing the clinical site) for at least 6 weeks. History of anti-PD-L1 only is not allowed.
•Progressive disease after anti PD-1 or anti-PD-L1 will be defined according to RECIST 1.
•The initial evidence of progressive disease is to be confirmed by a second assessment, no less than 4 weeks from the date of the first documented progressive disease, in the absence of rapid clinical progression. (This determination is made by the Investigator; the Sponsor will collect imaging scans for retrospective analysis. Once progressive disease is confirmed, the initial date of progressive disease documentation will be considered the date of disease progression).
•Documented disease progression within 12 weeks of the last dose of anti PD-1 or anti-PD-L
•Patients who were re-treated or on maintenance with anti-PD-1 or anti-PD-L1 will be allowed to enter the study as long as there is documented progressive disease within 12 weeks of the last treatment date.
•Naive to systemic therapy for RCC or have progressed after, or were intolerant of, prior systemic therapy.
•Measurable disease based on RECIST 1.1 criteria. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
•Karnofsky performance status of 70-100

Exclusion Criteria

•Known significant immunodeficiency due to underlying illness (e.g., human immunodeficiency virus \[HIV\] / acquired immune deficiency syndrome \[AIDS\]) and/or immune-suppressive medication including high-dose corticosteroids
•Part 2 only: Arm A,B,C: Prior treatment with any anti-cancer immunotherapy, including therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent (prior IL-2 or interferon allowed) . For Part 1: patients are excluded if they were intolerant to anti-PD-1 or anti-PD-L1 targeted therapies
•Major surgery within 4 weeks of study treatment (minor surgical procedures are allowed)
•Ongoing severe inflammatory skin condition requiring prior medical treatment
•History of eczema requiring prior medical treatment
•Tumor(s) invading a major vascular structure (e.g., carotid artery) or other key anatomical structure (e.g., pulmonary airway) OR viable central nervous system malignancy
•Clinically significant and/or rapidly accumulating ascites, pericardial and/or pleural effusions.
•Symptomatic cardiovascular disease, including but not limited to significant coronary artery disease (e.g., requiring angioplasty or stenting) or congestive heart failure within the preceding 12 months.
•Asymptomatic cardiovascular disease (current or past history) unless cardiology consultation and clearance has been obtained for study participation.
•Inability to suspend treatment with anti-hypertensive medication for 48 hours prior to and 48 hours after all Pexa-Vec treatments

Outcomes

Primary Outcomes

Maximum tolerated dose(MTD) / Maximum feasible dose (MFD)

Time Frame: 36 days after first treatment

MTD/MFD of Pexa-Vec administered by IV infusion in combination with Cemiplimab

Severity and frequency of adverse events to determine safety of Pexa-Vec administered by IV infusions or IT injections in combination with IV Cemiplimab

Time Frame: From date of first treatment until 28 days after last treatment

Safety will be determined by assessing the severity and frequency of adverse events and laboratory toxicity using CTCAE v4.03

Overall response rate

Time Frame: Every 9 weeks, then every 12 weeks after 1 year until date of first documented progression, up to 72 months

Evaluate anti-tumor activity and efficacy of IV or IT Pexa-Vec combined with IV Cemiplimab with respect to overall response rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1)

Secondary Outcomes

Progression free survival(Every 9 weeks, then every 12 weeks after 1 year until date of first documented progression, up to 72 months)
Disease control rate(Every 9 weeks, then every 12 weeks after 1 year until date of first documented progression, up to 72 months)
Best radiographic response(Every 9 weeks, then every 12 weeks after 1 year until date of first documented progression, up to 72 months)
Overall survival(Every 9 weeks, then every 12 weeks after 1 year until date of death from any cause, up to 72 months)